WCN25-2007 Evaluation of treatment strategy in patients with IgA nephropathy with impaired renal function

WCN25-2007 Evaluation of treatment strategy in patients with IgA nephropathy with impaired renal function

Saved in:

Bibliographic Details
Main Authors:	Ryousuke Aoki, Hitoshi Suzuki, Keiichi Matsuzaki, Masahiro Muto, Yoshihito Nihei, Yusuke Suzuki
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924024197
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-1435 VISUALIZATION OF THE MESANGIAL-CELL-SURFACE AUTOANTIGENS IN IGA NEPHROPATHY
by: Kazuaki Mori, et al.
Published: (2025-02-01)

WCN24-1104 Finding of CD4+ T cells infiltrating the kidney of gddY mouse, IgA nephropathy animal model
by: Hiroyuki Iwasaki, et al.
Published: (2024-04-01)

LIF/JAK2/STAT1 Signaling Enhances Production of Galactose-Deficient IgA1 by IgA1-Producing Cell Lines Derived From Tonsils of Patients With IgA Nephropathy
by: Koshi Yamada, et al.
Published: (2024-02-01)

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-1709 Salivary and Urinary Metabolomics Study in IgA Nephropathy Patients
by: Rümeyza Kazancıoğlu, et al.
Published: (2025-02-01)

WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)

WCN25-4090 The Diagnostic potential of Serum Gd-IgA1 to C3 ratio in IgA nephropathy: A single center prospective study
by: Ravi tej Madipalli, et al.
Published: (2025-02-01)

WCN25-1471 IgA Nephropathy with Anti-Neutrophil Cytoplasmic Antibodies in a Middle-Aged Patient
by: Giovanna Yazmin Arteaga Müller, et al.
Published: (2025-02-01)

IgA Nephropathy in the Elderly
by: Dana V. Rizk, et al.
Published: (2025-08-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2025-02-01)

A Case of IgA Nephropathy in a Patient With Sarcoidosis: Confirmation of Glomerular Galactose-Deficient IgA1 Deposition
by: Yoshitaka Shimizu, et al.
Published: (2025-01-01)

WCN25-1128 IgA DOMINANT INFECTION RELATED GLOMERULONEPHRITIS
by: Fatima Alkindi, et al.
Published: (2025-02-01)

Corrigendum to “Is childhood IgA nephropathy different from adult IgA nephropathy? A narrative review”
Published: (2025-07-01)

Aberrantly Glycosylated IgA1 as a Factor in the Pathogenesis of IgA Nephropathy
by: Mototsugu Tanaka, et al.
Published: (2011-01-01)

Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.
by: Qiang Sun, et al.
Published: (2016-01-01)

Carboxymethyl-lysine is a Prominent Target of Circulating IgA in IgA Nephropathy
by: Sara Alibrandi, et al.
Published: (2025-07-01)

WCN25-4466 Baseline parameters of IgA Nephropathy Using the Oxford MEST Score: Insights from the I-TANGIBLE Registry
by: Kavita Yadav, et al.
Published: (2025-02-01)

Opportunities and challenges in the treatment of IgA nephropathy
by: Yang Yang, et al.
Published: (2025-07-01)

Characterisation of IgA Nephropathy in an Australian Cohort
by: Shriram Swaminathan, et al.
Published: (2025-01-01)

Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy
by: Hiroyuki Ueda, et al.
Published: (2025-07-01)

Dabigatran-Related Nephropathy in a Patient with Undiagnosed IgA Nephropathy
by: Rachele Escoli, et al.
Published: (2015-01-01)

Serum IgA/C3 ratio as a diagnostic and prognostic biomarker for IgA nephropathy
by: Anitha Swamy, et al.
Published: (2025-08-01)

Cellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune Disease
by: Colin Reily, et al.
Published: (2014-01-01)

WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
by: Lisa Kivman, et al.
Published: (2025-02-01)

Effect and Safety of Finerenone in Patients with IgA Nephropathy
by: Guo Y, et al.
Published: (2025-07-01)

The pathogenesis of CD4~+ T lymphocytes in IgA nephropathy
by: 唐余燕, et al.
Published: (2020-01-01)

Clinicopathological analysis of IgA nephropathy combined with hyperuricemia
by: CAI Wei-cheng, et al.
Published: (2016-01-01)

Related factors of hyperuricemia in patients with IgA nephropathy
by: Li Yu-feng, et al.
Published: (2021-01-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-1664 Epidemiology, disease burden and treatment patterns for primary IgA nephropathy patients: A real-world data study in The Netherlands
by: Thom Lysen, et al.
Published: (2025-02-01)

WCN25-3679 Open label, single arm, multicenter, prospective study on oral enteric coated budesonide therapy for primary IgA nephropathy
by: SANSHRITI CHAUHAN, et al.
Published: (2025-02-01)

A Targeted-Release Formulation of Budesonide for the Treatment of IgA Nephropathy Patients With Severe Renal Impairment
by: Yan Ouyang, et al.
Published: (2025-03-01)

WCN25-4245 A CASE SERIES OF CONCURRENT IGA NEPHROPATHY AND ANTI- GBM DISEASE
by: Priyangani Lohia, et al.
Published: (2025-02-01)

Clinical and diagnostic significance of isolated detection of IgA antibodies to deamidated gliadin peptides in IgA nephropathy patients
by: M. E. Mantsaeva, et al.
Published: (2025-05-01)

Dynamics of chromatin accessibility governing Gd-IgA1 synthesis in B cells associated with IgA nephropathy
by: Yangang Gan, et al.
Published: (2025-07-01)

Lysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy
by: Meijun Si, et al.
Published: (2025-07-01)

Personal thoughts of IgA nephropathy and purpura nephritis in children
by: Zhang Hong-wen
Published: (2022-07-01)